23.25

2.92% -0.70

Neurogene Inc (NGNE)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$23.95

Aprire:

$24

Volume 24 ore:

571.50K

Relative Volume:

1.45

Capitalizzazione di mercato:

$465.26M

Reddito:

$925.00K

Utile/perdita netta:

$-98.64M

Rapporto P/E:

-4.6323

EPS:

-5.0191

Flusso di cassa netto:

$-83.37M

1 W Prestazione:

-11.93%

1M Prestazione:

-32.94%

6M Prestazione:

-9.29%

1 anno Prestazione:

-31.60%

Intervallo 1D:

$23.00

$24.27

Intervallo di 1 settimana:

$21.05

$27.15

Portata 52W:

$15.93

$43.66

Neurogene Inc Stock (NGNE) Company Profile

Nome

Neurogene Inc

Settore

Healthcare (1052)

Industria

Biotechnology (594)

Telefono

(877) 237-5020

Indirizzo

535 W 24TH STREET, NEW YORK

Dipendente

131

Cinguettio

Prossima data di guadagno

2026-11-12

Ultimi documenti SEC

NGNE's Discussions on Twitter

Compare NGNE vs VRTX, MRNA, REGN, ARGX, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
NGNE Neurogene Inc	23.25	465.26M	925.00K	-98.64M	-83.37M	-5.0191
VRTX Vertex Pharmaceuticals Inc	499.74	126.66B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	218.01	87.04B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	790.74	81.41B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	819.14	51.51B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	369.06	41.75B	5.76B	514.49M	1.10B	4.4813

Neurogene Inc Stock (NGNE) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-10-08	Iniziato	JP Morgan	Overweight
2026-06-03	Iniziato	Rodman & Renshaw	Buy
2025-06-17	Iniziato	Craig Hallum	Buy
2025-05-16	Downgrade	Robert W. Baird	Outperform → Neutral
2024-06-27	Iniziato	BMO Capital Markets	Outperform
2024-06-11	Iniziato	Robert W. Baird	Outperform
2024-04-29	Iniziato	Leerink Partners	Outperform
2024-03-21	Iniziato	William Blair	Outperform
2024-01-08	Iniziato	H.C. Wainwright	Buy
2024-01-05	Iniziato	Stifel	Buy
2024-01-04	Iniziato	TD Cowen	Outperform

Mostra tutto

Neurogene Inc Borsa (NGNE) Ultime notizie

Oct 13, 2026

Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects? - Zacks Investment Research

Oct 13, 2026

Oct 07, 2026

Prudential reports a passive Neurogene (NGNE) stake spanning more than 2 million shares. - Stock Titan

Oct 07, 2026

Oct 06, 2026

A passive investor reports 2.23 million shares of Neurogene (NGNE). - Stock Titan

Oct 06, 2026

Oct 05, 2026

Five new hires’ options vest over four years, if they stay - Stock Titan

Oct 05, 2026

Oct 02, 2026

Form 4 Neurogene Inc For: 2 October By Investing.com - Investing.com South Africa

Oct 02, 2026

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com

Sep 07, 2026

Sep 04, 2026

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com

Sep 04, 2026

Aug 30, 2026

Certain Stock Options of Neurogene Inc. are subject to a Lock-Up Agreement Ending on 31-AUG-2026. - marketscreener.com

Aug 30, 2026

Certain Pre-Funded Warrants of Neurogene Inc. are subject to a Lock-Up Agreement Ending on 31-AUG-2026. - marketscreener.com

Aug 30, 2026

Aug 20, 2026

Balyasny Asset Management L.P. Expands Neurogene Inc (NGNE) Stak - GuruFocus

Aug 20, 2026

Neurogene (NGNE) Watch: Posts a 4.45% Loss to $37.67 in the Current Update; Trading Range: Support at $35.79 and Resistance at $39.55 Frame the Range on the DayMarket Leader Picks - vinanet.vn

Aug 20, 2026

Neurogene (NGNE) Latest Quarter: Profit Per Share Falls Below Its Benchmark in Latest Trading; Market Response: Shares Finish 10.54% Higher in the Current UpdateLong-Term Guidance - dars.gov.et

Aug 20, 2026

Neurogene (NGNE) Latest Quarter: Profit Per Share Falls Below Its Benchmark in Latest Trading; Market Response: Shares Finish 10.54% Higher in the Current UpdateFull Year Guidance - vinanet.vn

Aug 20, 2026

Aug 19, 2026

Neurogene (NGNE) Results at a Glance: The Bottom-Line Figure Trails Its Comparison in the Latest Reading; Market Response: Shares Rise 10.54% for the Current SessionGuidance Upgrade Report - vinanet.vn

Aug 19, 2026

Neurogene gearing up to apply for approval of Rett gene therapy - Rett Syndrome News

Aug 19, 2026

Neurogene (NGNE) Results at a Glance: The Bottom-Line Figure Trails Its Comparison in the Latest Reading; Market Response: Shares Rise 10.54% for the Current SessionBalance Sheet Strength - dars.gov.et

Aug 19, 2026

Aug 16, 2026

NGNE Q1 2026 Earnings: Narrow EPS Miss Masks Positive Investor SentimentEarnings Forecast Report - vinanet.vn

Aug 16, 2026

Neurogene (NGNE) Gains 1.43% to $36.14: Key Resistance at $37.95 in FocusMoney Flow Index - vinanet.vn

Aug 16, 2026